Micromet names Ulrich Grau COO
This article was originally published in Scrip
Micromet, a cancer drug developer, has named Ulrich Grau its first chief operating officer, as well as executive vice-president. Mr Grau has more than 30 years' experience in the biotech and pharma industries, having most recently served as CEO of Lux Biosciences, a clinical stage private ophthalmic company that he co-founded.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.